These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 26765484)

  • 1. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
    Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
    Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease.
    Elbarbary NS; Ismail EA; Roushdy A; Fahmy E
    Blood Cells Mol Dis; 2016 Mar; 57():1-7. PubMed ID: 26852648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
    Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
    Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Predictive Value of Cystatin C in Pediatric Sickle Cell Disease: A Marker of Disease Severity and Subclinical Cardiovascular Dysfunction.
    Tantawy AAG; Adly AAM; Ismail EAR; Abdelazeem M
    Clin Appl Thromb Hemost; 2017 Nov; 23(8):1010-1017. PubMed ID: 27582023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications.
    Tantawy AA; Adly AA; Ismail EA; Habeeb NM; Farouk A
    Platelets; 2013; 24(8):605-14. PubMed ID: 23249216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease.
    Musiał K; Zwolińska D
    Clin Chim Acta; 2012 Dec; 414():7-11. PubMed ID: 22898262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD163 in young sickle cell disease patients and their trait siblings: a biomarker for pulmonary hypertension and vaso-occlusive complications.
    Tantawy AA; Adly AA; Ismail EA
    Blood Coagul Fibrinolysis; 2012 Oct; 23(7):640-8. PubMed ID: 22885767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
    Jun EJ; Han JY; Sun HS
    Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
    Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological role of CD4
    ElAlfy MS; Adly AAM; Ebeid FSE; Eissa DS; Ismail EAR; Mohammed YH; Ahmed ME; Saad AS
    Immunol Res; 2018 Aug; 66(4):480-490. PubMed ID: 29926339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome.
    Doughty L; Clark RS; Kaplan SS; Sasser H; Carcillo J
    Pediatr Res; 2002 Dec; 52(6):922-7. PubMed ID: 12438671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis.
    Musiał K; Zwolińska D
    Apoptosis; 2011 Jul; 16(7):653-9. PubMed ID: 21516345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
    Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
    Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
    Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
    J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease.
    Daak AA; Elderdery AY; Elbashir LM; Mariniello K; Mills J; Scarlett G; Elbashir MI; Ghebremeskel K
    Blood Cells Mol Dis; 2015 Jun; 55(1):48-55. PubMed ID: 25976467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of sFAS and sFAS ligand expression during canine visceral leishmaniosis.
    Perosso J; Silva KL; Ferreira SÍ; Avanço SV; dos Santos PS; Eugênio Fde R; de Almeida BF; de Lima VM
    Vet Parasitol; 2014 Oct; 205(3-4):417-23. PubMed ID: 25260330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of plasma transferrin receptor, ferritin and inflammatory markers in children with sickle cell disease.
    Al-Saqladi AW; Bin-Gadeem HA; Brabin BJ
    Paediatr Int Child Health; 2012 Feb; 32(1):27-34. PubMed ID: 22525445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albuminuria, serum antioxidant enzyme levels and markers of hemolysis and inflammation in steady state children with sickle cell anemia.
    Itokua KE; Makulo JR; Lepira FB; Aloni MN; Ekulu PM; Sumaili EK; Bukabau JB; Mokoli VM; Longo AL; Kajingulu FM; Zinga CV; Nlandu YM; Engole YM; Akilimali PZ; Ngiyulu RM; Gini JL; Nseka NM
    BMC Nephrol; 2016 Nov; 17(1):178. PubMed ID: 27855647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
    Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
    Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.